Literature DB >> 1157053

Mechanisms of action of 6-thioguanine, 6-mercaptopurine, and 8-azaguanine.

J A Nelson, J W Carpenter, L M Rose, D J Adamson.   

Abstract

The effects of 6-thioguanine on purine biosynthesis and cell viability have been examined in H.Ep. 2 cells grown in culture. Toxicity is not reversed by aminoimidazolecarboxamide, suggesting that inhibition of purine biosynthesis de novo is not the sole mechanism of toxicity. Also, 6-(methylmercapto)purine ribonucleoside, a potent inhibitor of purine biosynthesis de novo, produces more marked reductions in cellular pools of purines than does 6-thioguanine without killing cells. There is no apparent inhibition by 6-thioguanosine 5'-monophosphate of other enzymes leading to the synthesis of guanosine 5'-triphosphate as determined in whole cells by measurements of radioactive hypoxanthine or guanine incorporation. Inhibition of DNA synthesis by 1 mM thymidine protects cells from 6-mercaptopurine or 6-thioguanine but fails to protect cells from 8-azaguanine toxicity. On the other hand, inhibition of RNA synthesis by 6-azauridine plus deoxycytidine protects cells against 8-azaguanine but does not protect against 6-thioguanine or 6-mercaptopurine toxicity. In agreement with the in vitro data, arabinosylcytosine (a potent inhibitor of DNA synthesis) fails to protect mice against 8-azaguanine but has previously been shown to protect mice from 6-mercaptopurine or 6-thioguanine toxicity. The results support the hypotheses of others that incorporation into DNA (as 6-thioguanine nucleotide) is a mechanism of toxicity for these thiopurines, whereas 8-azaguanine is toxic due to its incorporation into RNA.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157053

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Phase II trial of 5 day continuous intravenous infusion of 6-thioguanine in patients with recurrent and metastatic squamous cell carcinoma of the head and neck.

Authors:  F Kruter; M Eisenberger; V Sinibaldi; C Engstrom; M Jacobs; J Abrams; C Belani; W Gray; S Krasnow
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

2.  Synthesis of oligonucleotides containing 2'-deoxy-6-thioguanosine at a predetermined site.

Authors:  M S Christopherson; A D Broom
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

3.  Cross Talk between Nucleotide Synthesis Pathways with Cellular Immunity in Constraining Hepatitis E Virus Replication.

Authors:  Yijin Wang; Wenshi Wang; Lei Xu; Xinying Zhou; Ehsan Shokrollahi; Krzysztof Felczak; Luc J W van der Laan; Krzysztof W Pankiewicz; Dave Sprengers; Nicolaas J H Raat; Herold J Metselaar; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Antiviral screening identifies adenosine analogs targeting the endogenous dsRNA Leishmania RNA virus 1 (LRV1) pathogenicity factor.

Authors:  F Matthew Kuhlmann; John I Robinson; Gregory R Bluemling; Catherine Ronet; Nicolas Fasel; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

5.  Basal ganglia dopamine loss due to defect in purine recycling.

Authors:  Kiyoshi Egami; Silaja Yitta; Suhail Kasim; J Chris Lewers; Rosalinda C Roberts; Mohamed Lehar; H A Jinnah
Journal:  Neurobiol Dis       Date:  2007-02-08       Impact factor: 5.996

6.  6-Thioguanine inhibition of parathyroid hormone-related protein expression is mediated by GLI2.

Authors:  Rachelle W Johnson; Alyssa R Merkel; Sabrina Danilin; Mai P Nguyen; Gregory R Mundy; Julie A Sterling
Journal:  Anticancer Res       Date:  2011-09       Impact factor: 2.480

7.  Phase II trial of 6-thioguanine in advanced renal cell carcinoma. An Illinois Cancer Center study.

Authors:  D H Shevrin; L J Kilton; T E Lad; M Mullane; B Esparaz; R Knop; J Egner; P Johnson; R Blough; S French
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

8.  6-Thioguanine: high-dose 2-H infusions in goats.

Authors:  T J Schouten; R A De Abreu; E D Schretlen; M B van Leeuwen; J M van Baal; G A de Vaan
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

9.  Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts.

Authors:  E H Stet; R A De Abreu; J P Bökkerink; H J Blom; L H Lambooy; T M Vogels-Mentink; A C de Graaf-Hess; B van Raay-Selten; F J Trijbels
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

10.  A novel class of unstable 6-thioguanine-resistant cells from dog and human kidneys.

Authors:  M S Turker; R J Monnat; K Fukuchi; P A Johnston; C E Ogburn; R E Weller; J F Park; G M Martin
Journal:  Cell Biol Toxicol       Date:  1988-06       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.